Free Newsletter

FEATURES >> 15 Top Blockbuster Contenders | 10 Promising Therapeutic Vaccines

Related Topics >> heart disease | protein | Schering-Plough

SPOTLIGHT: Schering-Plough touts potential of new drug

January 8, 2007 — 7:01pm ET

ALSO NOTED: Agennix OK'd to launch late-stage lung cancer trial; QLT reorganizes; Ventana still resisting Roche bid; and much m
Cytokinetics, Amgen ink heart drug deal
Researchers say Gleevec linked to heart damage
InNexus blueprints protein-manufacturing plant
Pioneering stem cell therapy mends damaged heart tissue in patients

Tools

Subscribe
Email
Print
Contact Author
Reprint

Schering-Plough is bullish about its experimental anti-clotting drug, saying it could be a potentially transformational product that can significantly reduce the risk of heart attack and stroke without raising the risk of bleeding. The drug prevents thrombin, a clot-causing protein, from attaching to platelets. Report

SHARE
WITH: